Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
$5.84
$0.35(10.45%)
At close: 4:00 PM EST
$5.84
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.30 - $7.89
Previous CloseN/A
Volume116.73K
Average Volume (3M)63.15K
Market Cap
$654.83M
Enterprise Value$387.89M
Total Cash (Recent Filing)$72.21M
Total Debt (Recent Filing)$13.50M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding85,264,145
10 Day Avg. Volume63,869
30 Day Avg. Volume63,150
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)3.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.30
Forecast
1Y Price Target
$7.00Price Target Upside19.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsEarly clinical results showing an 81% disease control rate and measurable tumor responses in a first-in-human pancreatic cancer study indicate potential meaningful benefit in a hard-to-treat indication.
Manufacturing Scale-upReceipt of a radioactive material license and plans to equip a New Hampshire commercial facility capable of large-scale source production support readiness for scaled U.S. supply and a potential manufacturing start in 2026.
Regulatory MomentumBreakthrough Device designation, FDA permission for a modular PMA review, and multiple IDE approvals reflect regulatory engagement that could streamline approval pathways for the device across tumor types.
Bears Say
Commercialization DelaysRevised expectations for U.S. commercialization timelines raise the risk of a slower revenue ramp and extend the period before widespread clinical adoption occurs.
Limited International LaunchA planned soft launch in Japan rather than an immediate full commercial release could limit early market penetration and postpone broader post-market sales data needed for future approvals.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.30 and its highest was $7.89 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $654.83M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Mar 05, 2026 which is in 46 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Nov 20, 2025. The company reported -$0.149 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.038.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.12.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 85,264,145 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.149 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 10.086%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (19.86% Upside)
$7.00 (19.86% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
-54.38%
Trailing 12-Months
Asset Growth
15.39%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$7.00
▲(19.86% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.65% Other Institutional Investors
99.31% Public Companies and
Individual Investors